Gilead’s second-quarter Sovaldi sales increased from $2.3 billion during the first quarter of this year — the first full quarter of sales since the drug’s approval in December 2013. Analysts estimate Sovaldi will surpass $10 billion in sales this year, according to a report in The New York Times.
Since its approval, Sovaldi has been prescribed to more than 80,000 people in the U.S. and Europe, and the drug has a success rate of more than 90 percent. However, the Sovaldi’s high price tag has drawn criticism from many, including lawmakers.
The typical 12-week drug regimen of Sovaldi costs $84,000, but some patients require the drug for a longer period of time. Guidelines also suggest taking the drug along with others, adding to the overall care costs.
Earlier this month, Sens. Ron Wyden (D-Ore.), chairman of the Senate Finance Committee, and Chuck Grassley (R-Iowa), the Judiciary Committee’s ranking member, sent a letter seeking justification from Gilead for Sovaldi’s hefty price tag.
“Given the impact Sovaldi’s cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug,” the senators wrote in the letter.
More Articles on Sovaldi:
60% of Americans Are Worried They Won’t Be Able to Afford Specialty Drugs
Lawmakers Question Why Sovaldi Costs $1k a Pill
UnitedHealth Group Q1 Hepatitis C Drug Spending Reached $100M
